Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study

Abstract

Background The Onduo virtual care program for people with type 2 diabetes (T2D) includes a mobile app, remote lifestyle coaching, connected devices, and telemedicine consultations with endocrinologists for medication management and prescription of real-time continuous glucose monitoring (RT-CGM) devices. In a previously described 4-month prospective study of this program, adults with T2D and baseline glycated hemoglobin (HbA1c) ≥8.0% to ≤12.0% experienced a mean HbA1c decrease of 1.6% with no significant increase in hypoglycemia. Objective The objective of this analysis was to evaluate medication optimization and management in the 4-month prospective T2D study. Methods Study participants received at least 1 telemedicine consultation with an Onduo endocrinologist for diabetes medication management and used RT-CGM intermittently to guide therapy and dosing. Medication changes were analyzed. Results Of 55 participants, 48 (87%) had a medication change consisting of a dose change, addition, or discontinuation. Of these, 15 (31%) participants had a net increase in number of diabetes medication classes from baseline. Mean time to first medication change for these participants was 36 days. The percentage of participants taking a glucagon-like peptide-1 receptor agonist increased from 25% (12/48) to 56% (n=27), while the percentages of participants taking a sulfonylurea or dipeptidyl peptidase 4 inhibitor decreased from 56% (n=27) to 33% (n=16) and 17% (n=8) to 6% (n=3), respectively. Prescriptions of other antidiabetic medication classes including insulin did not change significantly. Conclusions The Onduo virtual care program can play an important role in providing timely access to guideline-based diabetes management medications and technologies for people with T2D. Trial Registration ClinicalTrials.gov NCT03865381; https://clinicaltrials.gov/ct2/show/NCT03865381

Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial

“…In our study, use of anti‐hyperglycaemic medications with proven cardiovascular benefits increased by >2‐fold with CGM use, with a trend towards less sulphonylurea and DPP‐4 inhibitor use and more utilization of angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Similar to our findings, other CGM‐based studies have shown increased utilization of anti‐hyperglycaemic medications, including greater use of GLP‐1 receptor agonists and less use of sulphonylurea or DPP‐4 inhibitors 34 . Furthermore, although glycaemic control is not the target of blood pressure or lipid‐lowering medications, more intensive behavioural change and/or prescription practices to lower overall cardiovascular risk (e.g.…”

Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement

“…The participants of this study received real-time continuous glucose monitoring (RT-CGM) devices. Using a phone application and the data gathered from the devices, a care team was able to provide education and advice on lifestyle modification tailored to the patients’ needs ( 32 ), while making necessary therapy adjustments according to the actual recommendations of the ADA ( 33 ). Type 2 diabetic patients with HbA1c levels ranging from 8-12% were selected for the purposes of the study.…”